Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide

PHASE4CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

July 31, 2018

Study Completion Date

September 30, 2018

Conditions
Diabetes
Interventions
DRUG

Dapagliflozin

Dapagliflozin 10 mg, orally once daily at any time of day with or without food. If HbA1c does not decrease by \> 0.4% at 12 week, rescue therapy (sitagliptin 100 mg) can be added at investigator's discretion.

DRUG

Gliclazide

Gliclazide MR 30 mg, orally once daily at any time of day with or without food. If HbA1c does not decrease by \> 0.4% at 12 week, rescue therapy (gliclazide MR 30 mg) can be added at investigator's discretion.

Trial Locations (1)

463-707

Seoul National University Bundang Hospital, Seongnam-si

All Listed Sponsors
lead

Seoul National University Bundang Hospital

OTHER

NCT02610088 - Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide | Biotech Hunter | Biotech Hunter